中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2013年
12期
2061-2063,2065
,共4页
凯福隆%小儿化脓性脑膜炎
凱福隆%小兒化膿性腦膜炎
개복륭%소인화농성뇌막염
Cefotaxime Sodium%Pediatric purulent meningitis
目的：探讨头孢噻肟钠(凯福隆)治疗小儿化脓性脑膜炎作用机制研究。方法：自2009年3月~2011年9月我院接诊小儿化脓性脑膜炎患儿79例,均经临床表现、脑脊液检查、颅脑CT以及血常规检查等方法确诊。根据随机数字表法将79例患儿随机分为两组,即头孢唑肟治疗组、凯福隆治疗组,另选取健康同龄儿童30例作为健康对照组。分别通过ELISA、荧光定量PCR法以及蛋白免疫印迹(Westerblot)法,在药物治疗前及治疗后对细胞炎性因子中的肿瘤坏死因子α(TNF-α)、白介素6(IL-6)、白介素1β(IL-1β)以及基质金属蛋白-9(MMP9)的蛋白含量或者mRNA含量进行测定。分析相关药物的具体治疗机制。结果：ELISA法结果显示,相比于头孢唑肟组,凯福隆组在治疗后的炎性细胞因子的蛋白含量显著降低(P<0.01),同时通过荧光定量PCR法结果也保持一致,具有显著的统计学差异(P<0.01)。而通过蛋白免疫印迹法检测MMP-9蛋白含量发现,头孢唑肟组治疗后未有明显降低,而凯福隆组治疗后,MMP-9蛋白含量显著降低,具有显著的统计学差异(P<0.01)。结论：结合MMP-9在血脑屏障中的影响,凯福隆药物通过显著降低MMP-9水平从而改善患儿脑膜炎症状,为今后研究小儿细菌性及化脓性脑膜炎发病机制提供了一定的理论基础及实验基础。
目的：探討頭孢噻肟鈉(凱福隆)治療小兒化膿性腦膜炎作用機製研究。方法：自2009年3月~2011年9月我院接診小兒化膿性腦膜炎患兒79例,均經臨床錶現、腦脊液檢查、顱腦CT以及血常規檢查等方法確診。根據隨機數字錶法將79例患兒隨機分為兩組,即頭孢唑肟治療組、凱福隆治療組,另選取健康同齡兒童30例作為健康對照組。分彆通過ELISA、熒光定量PCR法以及蛋白免疫印跡(Westerblot)法,在藥物治療前及治療後對細胞炎性因子中的腫瘤壞死因子α(TNF-α)、白介素6(IL-6)、白介素1β(IL-1β)以及基質金屬蛋白-9(MMP9)的蛋白含量或者mRNA含量進行測定。分析相關藥物的具體治療機製。結果：ELISA法結果顯示,相比于頭孢唑肟組,凱福隆組在治療後的炎性細胞因子的蛋白含量顯著降低(P<0.01),同時通過熒光定量PCR法結果也保持一緻,具有顯著的統計學差異(P<0.01)。而通過蛋白免疫印跡法檢測MMP-9蛋白含量髮現,頭孢唑肟組治療後未有明顯降低,而凱福隆組治療後,MMP-9蛋白含量顯著降低,具有顯著的統計學差異(P<0.01)。結論：結閤MMP-9在血腦屏障中的影響,凱福隆藥物通過顯著降低MMP-9水平從而改善患兒腦膜炎癥狀,為今後研究小兒細菌性及化膿性腦膜炎髮病機製提供瞭一定的理論基礎及實驗基礎。
목적：탐토두포새우납(개복륭)치료소인화농성뇌막염작용궤제연구。방법：자2009년3월~2011년9월아원접진소인화농성뇌막염환인79례,균경림상표현、뇌척액검사、로뇌CT이급혈상규검사등방법학진。근거수궤수자표법장79례환인수궤분위량조,즉두포서우치료조、개복륭치료조,령선취건강동령인동30례작위건강대조조。분별통과ELISA、형광정량PCR법이급단백면역인적(Westerblot)법,재약물치료전급치료후대세포염성인자중적종류배사인자α(TNF-α)、백개소6(IL-6)、백개소1β(IL-1β)이급기질금속단백-9(MMP9)적단백함량혹자mRNA함량진행측정。분석상관약물적구체치료궤제。결과：ELISA법결과현시,상비우두포서우조,개복륭조재치료후적염성세포인자적단백함량현저강저(P<0.01),동시통과형광정량PCR법결과야보지일치,구유현저적통계학차이(P<0.01)。이통과단백면역인적법검측MMP-9단백함량발현,두포서우조치료후미유명현강저,이개복륭조치료후,MMP-9단백함량현저강저,구유현저적통계학차이(P<0.01)。결론：결합MMP-9재혈뇌병장중적영향,개복륭약물통과현저강저MMP-9수평종이개선환인뇌막염증상,위금후연구소인세균성급화농성뇌막염발병궤제제공료일정적이론기출급실험기출。
Objective:To explore the role of Cefotaxime Sodium on pediatric purulent meningitis. Methods:From 2009 March to 2011 September in our hospital with admissions of children with bacterial and purulent meningitis in 79 cases, which is through the clinical presentation, examination of cerebrospinal fluid, brain CT and blood routine examination and other methods confirmed. According to the random number table:79 patients were randomly divided into two groups, namely of Ceftizoxime in the treatment group,Cefotaxime Sodium group, in addition the other children of the same age in 30 cases of healthy as a healthy control group. Through ELISA, fluorescence quantitative PCR assay and Western blot (Westerblot )method, before and after medication take a few therapy on inflammatory cytokine production in tumor necrosis factorα(TNF-α),interleukin 6 (IL-6),interleukin 1β( IL-1β) and matrix metalloproteinase-9 (MMP-9).Protein content and mRNA content determination. Analysis of related drugs to specific treatment mechanism. Results:The ELISA method results show compared to Ceftizoxime group, Cefotaxime Sodium group after treatment on inflammatory cytokine protein content decreased significantly (P<0.01),at the same time by fluorescence quantitative PCR assay results are consistent, with significant statistical difference (P<0.01).Through protein immunoblot assay for detection of MMP-9 protein content discovery, Ceftizoxime group after treatment did not significantly decreased, and Cefotaxime Sodium group after treatment, the MMP-9 protein content was lower, with significant statistical difference (P<0.01). Conclusion:According to the role of MMP-9 in the blood brain barrier, Kefalo drugs with MMP-9 level significantly reduced so as to improve the patients symptoms of meningitis, this thesis of the paper on pediatric bacterial and purulent meningitis pathogenesis can be as the theoretical basis and experimental base.
